Smith & Nephew (SNN) & Amedica (AMDA) Head to Head Contrast

Smith & Nephew (NYSE: SNN) and Amedica (NASDAQ:AMDA) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, earnings, valuation and dividends.

Analyst Ratings

This is a summary of current ratings and recommmendations for Smith & Nephew and Amedica, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Smith & Nephew 0 3 2 0 2.40
Amedica 0 2 0 0 2.00

Smith & Nephew presently has a consensus price target of $45.00, suggesting a potential upside of 21.00%. Amedica has a consensus price target of $60.00, suggesting a potential upside of 1,675.15%. Given Amedica’s higher probable upside, analysts clearly believe Amedica is more favorable than Smith & Nephew.

Institutional and Insider Ownership

6.4% of Smith & Nephew shares are owned by institutional investors. Comparatively, 62.5% of Amedica shares are owned by institutional investors. 1.0% of Smith & Nephew shares are owned by company insiders. Comparatively, 0.1% of Amedica shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Volatility & Risk

Smith & Nephew has a beta of 0.72, suggesting that its share price is 28% less volatile than the S&P 500. Comparatively, Amedica has a beta of -2.08, suggesting that its share price is 308% less volatile than the S&P 500.

Profitability

This table compares Smith & Nephew and Amedica’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Smith & Nephew N/A N/A N/A
Amedica -71.07% -73.86% -36.96%

Dividends

Smith & Nephew pays an annual dividend of $0.61 per share and has a dividend yield of 1.6%. Amedica does not pay a dividend. Smith & Nephew pays out 31.1% of its earnings in the form of a dividend.

Earnings and Valuation

This table compares Smith & Nephew and Amedica’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Smith & Nephew $4.67 billion 3.49 $784.00 million $1.96 18.97
Amedica $15.23 million 0.67 -$14.76 million N/A N/A

Smith & Nephew has higher revenue and earnings than Amedica.

Summary

Smith & Nephew beats Amedica on 11 of the 14 factors compared between the two stocks.

About Smith & Nephew

Smith & Nephew plc is a medical technology company. The Company is engaged in developing, manufacturing, marketing and selling medical devices and services. Its products and services include Sports Medicine Joint Repair, Arthroscopic Enabling Technologies (AET), Trauma & Extremities, Other Surgical Businesses, Knee Implants, Hip Implants, Advanced Wound Care, Advanced Wound Bioactives and Advanced Wound Devices. The Sports Medicine Joint Repair franchise offers surgeons a range of instruments, technologies and implants necessary to perform minimally invasive surgery of the joints, including the repair of soft tissue injuries and degenerative conditions of the knee, hip and shoulder. The AET franchise offers an array of minimally invasive surgery-enabling systems and devices. The Trauma & Extremities franchise supports healthcare professionals with solutions used by surgeons to stabilize severe fractures, correct bone deformities, treat arthritis and heal soft tissue complications.

About Amedica

Amedica Corporation is a commercial biomaterial company. The Company is a vertically integrated silicon nitride orthopedic medical device manufacturer. It is focused on using its silicon nitride ceramic technology platform to develop, manufacture and sell a range of medical devices. It is also engaged in developing wear- and corrosion-resistant implant components for hip and knee arthroplasty. The Company markets its Valeo family of silicon nitride interbody spinal fusion devices in the United States, Europe and Brazil for use in the cervical and thoracolumbar areas of the spine. In addition to its silicon nitride-based spinal fusion products, it markets a line of non-silicon nitride spinal surgery products, which allows the Company to provide surgeons and hospitals with a solution for spinal procedures. Its Valeo interbody spinal fusion devices include Anterior Lumbar, Posterior Lumbar, Oblique Lumbar, Transforaminal Lumbar, Lateral Lumbar, Cervical and Corpectomy.

Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply